Patient Square Capital’s Merck MRK Stock Holding History

Patient Square Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80,000	Closed	-$9.62M	–	32
2026 Q1	$9.62M	Buy	+80,000	New	+$9.24M	1.71%	16

Other funds holding MRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Patient Square Capital's MRK Position: Q2 2026 in Review

Patient Square Capital sold out of Merck (MRK) in Q2 2026, closing a stake of 80,000 shares — an estimated $9.62M sold.

Patient Square Capital first reported a position in MRK in Q1 2026 and held it in 1 quarter. The position peaked at $9.62M in Q1 2026. 3,845 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

Patient Square Capital reported no remaining Merck position as of Q2 2026 after selling out during the quarter.
Patient Square Capital sold 80,000 Merck shares in Q2 2026, an estimated $9.62M.
Patient Square Capital first reported a position in Merck in Q1 2026 and held it in 1 quarter.
Patient Square Capital's Merck position peaked at $9.62M in Q1 2026.
3,845 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.